Drug Trial Radar · NCT03675282
Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls
Last checked: Nov 20, 2026Latest source record: Mar 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
82
Actual
Start
Aug 14, 2018
Primary completion
Apr 23, 2024
Study completion Apr 23, 2024
Sponsor
- Lead sponsor
- Weill Medical College of Cornell UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Neurological Disorders and Stroke (NINDS)
- First posted
- Sep 18, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 20 years, up to 100 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Prospective, single center study to determine whether the current R2\* iron mapping method for measuring nigral iron changes in the brain can be significantly improved by using the Quantitative Susceptibility Mapping (QSM) based iron mapping techniques with the goal of validating QSM for potential use in later clinical trials. Subjects with a diagnosis of Parkinson's Disease, Rapid Eye Movement (REM) Sleep Behavior Disorder, and Normal Volunteers who meet the inclusion and exclusion criteria will be eligible for participation in this study.
Conditions
- Parkinson Disease
- REM Sleep Behavior Disorder
- Healthy
Interventions
(11C)PE2IDrug
Subjects will received (11C)PE2I PET Scans at Baseline and 24 Month Visits
IoflupaneDrug
Subjects will receive a DaT scan at baseline and 24 month visits if they don't receive a PE2I PET scan at baseline and 24 month visits
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Sensitivity of QSM MR Imaging From Baseline MR Imaging to 24 Month MR ImagingTime frame: Baseline and 24 Months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital for Special Surgery
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.